16th World ADC London 2026

With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs provide meaningful impact to patients in need.

Returning as the longest-standing and definitive ADC forum in Europe, the 16th World ADC London is the week for anyone working in or interested to learn about bioconjugates. Leverage cutting-edge R and D, development strategy, and unparalleled networking opportunities to harness ADC innovation and maximise the therapeutic index of your ADCs.

With 5 streams of end-to-end content spanning discovery, preclinical and translation, clinical lessons, process and analytical development, and manufacturing and supply chain: the 2026 agenda has been infused with trailblazing design, development, and production innovations to overcome patient resistance mechanisms and push ADCs to earlier line oncology treatments.

Uniting 800+ senior European ADC decision-makers across biopharma, clinicians, service providers, investors, and regulators, World ADC London is proud to bring the community together to kick off 2026 and shape the future of ADC development.

URLs:
Website: https://go.evvnt.com/3298052-0?pid=2874
Brochure: https://go.evvnt.com/3298052-3?pid=2874

Category: Conferences | Health

Prices:
Conference + Seminar Day + Workshop Day - Drug Developer Pricing: GBP 4765.00,
Conference + Seminar Day or Workshop Day - Drug Developer Pricing: GBP 3767.00,
Conference Only - Drug Developer Pricing: GBP 2769.00,
Conference + Seminar Day + Workshop Day - Academic Pricing: GBP 3915.00,
Conference + Seminar Day or Workshop Day - Academic Pricing: GBP 3117.00,
Conference Only - Academic Pricing: GBP 2319.00,
Conference + Seminar Day + Workshop Day - Service Provider Pricing: GBP 6475.00,
Conference + Seminar Day or Workshop Day - Service Provider Pricing: GBP 4997.00,
Conference Only - Service Provider Pricing: GBP 3519.00

Speakers: Ali Warbington, Director, Toxicology, AbbVie, Ronnie Yeager, Research Fellow, Emerging Therapeutic Platforms, AbbVie, Shilpen Patel, Executive Medical Director, Oncology, and Global Development Lead, AbbVie, Johanna Midelet, Director - Bioconjugation and Chemistry, Abzena, Gavin Birch, Chemistry Manager, Abzena, Zhenwei Miao, Founder and Chairman, Adcoris Biopharma, Sonia Appel, Founder, Alismere, Marija Vrljic, Vice President, Antibody Technologies, ALX Oncology, Herbert Ogutu, Senior Manager, Contract Development and Manufacturing, Amgen, Alan Russell, Vice President, Research and Head, R and D Technology and Innovation, Amgen, Anne-Sophie Pailhes-Jimenez, Senior Director Head of Research and Development, ANGLE, Martha Neagu Ariside, Senior Medical Director, AbbVie, Jasmine Lichfield, Clinical Lead, Astellas Pharma, Guzin Sahan, Associate Director, CMC Regulatory Affairs, AstraZeneca, Osama Chahrour, Principal Scientist, Chemical Development, AstraZeneca, Elaine Hurt, Executive Director and Head, Tumour Targeted Delivery Bioscience, Oncology R and D, AstraZeneca, Balakumar Vijayakrishnan, Director, Bioconjugation and Analytical, AstraZeneca, Niresh Hariparsad, Head, DMPK Boston, Oncology R and D, AstraZeneca, Suzanne Randle, Associate Director, Oncology Targeted Discovery Safety, AstraZeneca, Shujing Wang, Senior Director, Drug Product Development, AsymBio, Hanhua Huang, Vice President Avidity, Biosciences, Bertrand Cottineau, R and D Group Head, Axplora, Melanie Derde, Head, Bioconjugation Operations, Axplora, Jake Morris, Manager, Commercial, Beacon by Hanson Wade, Yu-Shin Hsu, Research Analyst Lead, Beacon by Hanson Wade, Javad Shahidi, Senior Vice President, Biotech Unit, BeOne Medicines, Gavin Bennett, Senior Director, BTC Portfolio Lead, Bicycle Therapeutics, Benny Yang, Chief Scientific Officer, Biocytogen, Rakesh Dixit, President and Chief Executive Officer, Bionavigen Oncology, David Bramhill, President and Founder Bramhill, Biologics Consulting, Jonathan Tobin, Partner, Brandon Biocapital, Giorgio Salciarini, Head, Sales and Technical Business Development, BSP Pharmaceuticals, Renier Heijkants, Lead Scientist, Byondis, Ruud Coumans, Project Leader, Byondis, Eef Dirksen, Head, Analytical Validation and Quality Control, Byondis, Ayodele Ogunkoya, Group Leader, Bioconjugation, Catalent, Lena Jonsson, Product Strategy Manager, Cytiva, Sean McCarthy, Chief Executive Officer, CytomX Therapeutics, David Leung, Head, Imaging, Daiichi Sankyo, Guillaume Bergthold, Executive Director, Clinical Development, Daiichi Sankyo, Zenta Tsuchihashi, Senior Director, Translational Patient Safety, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Leo Marx, Head, ADC Research and Technologies, Debiopharm, Paolo Tarantino, Clinical Research Fellow, DFCI, Stefano Zanotti, Senior Vice President and Head, Neuromuscular Research, Dyne Therapeutics, Daniel Bending, Postdoctoral Researcher, Eli Lilly and Co., Eunice Yuen, Director, PK/PD and Pharmacometrics, Eli Lilly and Co., Thierry Guillaudeux, Executive Director and Head, R and D France, Eli Lilly and Co., Venkatesh Pilla, Reddy Senior Director, Global PKPD and Pharmacometrics, Eli Lilly and Co., Paul Song, Chief Scientific Officer, GeneQuantum Healthcare, Daniel Chen, Partner and Co-Founder, Genesis BioCapital, Bas Rosier, Scientist, Functional Characterisation and Bioassays, Genmab, Antoine Venne, Scientist, Process Development, Gilead Sciences, Caity Fawcett, Senior Scientist, GSK, David Battersby, Team Leader, Associate Fellow, GSK, Luisa Freitas dos Santos, Vice President - Global Clinical Supply Chain, GSK, Sue Griffin, Vice President, Translational Haematology and Tumour Omics, Oncology Translational Research, GSK, Harry Copping, Industrial PhD Student, GSK and University of Strathclyde, Matthieu Culie, Head, mAb and ADC Development and GMP Manufacturing, GTP Bioways, Peng Guo, Professor Hangzhou, Institute of Medicine, Alistair Ellmer, Research Director, Hanson Wade Intelligence, Andras Strassz, Chief Medical Officer, Heidelberg Pharma, Jonathan Davis, Director, ADC Discovery, Helix Biopharma, Justin Mason-Home, Director, HPAPI Project Services Limited, Eider Valle-Encinas, Scientific Business Development Manager, HUB Organoids, Jutta Deckert, Vice President, R and D, Iksuda Therapeutics, Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics, Greg Adams, Consultant, Independent Consultant, Hans-Georg Lerchen, Consultant Independent, Consultant, Elisabetta Leo, Senior Director, Early Development Asset Lead, Ipsen Pharma, Jon Travers, Senior Director, External Innovation and Early Development, Ipsen Pharma, Eugenio Cardenal, Associate Director, CMC Regulatory Affairs, Johnson and Johnson, Mohit Trikha, President and Chief Operating Officer, Kivu Bioscience, Simon Jiang, Vice President, Biology and Head, Scientific Engagement, Lide Biotech, Andre Unglert, Director, Commercial Development, Bioconjugates, Lonza, Michael Trose, Manager, Process Technologist, MSAT Bioconjugates, Lonza, Deryk Loo, Vice President, MacroGenics, Shyam Masrani, Partner, Medicxi, Robert Guilmett, Group Lead, Process and Analytical Development, Merck, Mary Ramisetty, Senior Scientist and Group Lead, Merck, Lisa McDermott, Director, Senior Manager and Principal Scientist - Process and Analytical Development, Merck, Wenyong Tong, Principal Scientist, MSD, Ryan O’Hara, Director, Biologics Technical Operations, MSD, Michael Seganish, Distinguished Scientist, Discovery Chemistry, MSD, Xiaoxiao Wang, Vice President, Antibody Discovery and ADC Platform, Nona Biosciences, Tim Mollner, Senior Expert, Science and Technology, Novartis, Ya-Chi Chen, Chief Scientific Officer, OBI Pharma, Christian Rohlff, Chief Executive Officer Oxford, BioTherapeutics, Christian Merz, Assessor, Non-Clinical/Quality, Antibody Therapeutics, Paul Ehrlich Institute, Natalie Grinshtein, Director - ADC Biology and Oncology, Pfizer, Philip Moquist, Director, ADC Chemistry, Pfizer, Alain Beck, Senior Director, Biologics CMC Developability, Pierre Fabre, Conor Barry, Associate Vice President and Global Head, Bioconjugate Development Piramal, Pharma Solutions, Daniel Schulz-Jander, Senior Director, Bioanalysis (Mass Spectrometry), QPS, Robert Brooks, Chief Executive Officer Radiance, Biopharma, Ines Matos, Principal Scientist, Roche, Sam Murphy, Chief Executive Officer, Salubris Bio, Irena Adkins, Director Pharmacology, SOTIO Biotech, Sarka Stehlikova, Director, Biologics Core Technologies, SOTIO Biotech, Hanspeter Gerber, Chief Scientific Officer, Sutro Biopharma, Floris van Delft, Head, R and D, Synaffix, a Lonza Company